The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0909 ET – Sartorius might benefit from opportunities arising ...

Ideaya Biosciences (IDYA) and Jiangsu Hengrui Pharmaceuticals Co. announced the publication of an abstract for an oral presentation on IDE849 at ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

Access detailed information about the Jiangsu Hengrui Pharmaceuticals Co Ltd (1276) Share including Price, Charts, Technical Analysis, Historical data, Jiangsu Hengrui Pharmaceuticals Reports and more ...

Chairman of Oakwise Capital says wealthy mainland Chinese will continue looking to Hong Kong as a home for their family ...

HONG KONG] A parade of China’s mega listings in Hong Kong since the turn of the year has helped restore some of the shine to ...

The sale represents Clever Culture’s fifth engagement with a leading pharma manufacturer, including AstraZeneca, Bristol Myers Squibb and Thermo Fisher. The company is due to report its Q4 FY25 ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

In this week’s edition of InnovationRx, we look at how Daniel Nadler became a billionaire building a ChatGPT for doctors, big ...

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...